efavirenz
efavirenz: 7 clinical trials tracked.
efavirenz evidence translation
What we can confirm
7 tracked trials
What it means
What to watch
Prepared research question
What is verified about efavirenz, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence4 indications · 2 study sponsors
Related indications
Clinical Trial Registry Records (7)
The Drug-Drug Interaction Study of Clifutinib
Primary endpoint: Cmax
A Phase 1, Open-label Drug-drug Interaction Study to Evaluate the Effects of Efavirenz on the Pharmacokinetics of Suzetrigine in Healthy Subjects
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of SUZ and its Metabolite in the Absence and Presence of Efavirenz
A Phase I, Randomized, Open-label, Drug-drug Interaction Study to Assess the Effect of Multiple Doses of a Moderate and a Strong CYP3A Inducer on the Pharmacokinetics and Safety of Mavorixafor in Healthy Male and Female Participants
Primary endpoint: Cohort 1: Maximum Observed Plasma Concentration (Cmax) of Mavorixafor Without (Day 1) and With (Day 18) Coadministration With Carbamazepine
A Single Sequence, 2-Period, Open-label Crossover Study in Healthy Subjects to Determine the Effect of a Moderate CYP3A4 Inducer on the Pharmacokinetics of Omaveloxolone
Primary endpoint: Maximum concentration (Cmax) of omaveloxolone
Pilot Trial Evaluating Once Daily Triple Combination Antiretroviral Therapy With Tenofovir-Emtricitabine and Efavirenz in HIV-1 Infected Patients With Mycobacterium Tuberculosis Infection ANRS129 BKVIR
Primary endpoint: treatment success rate at week 48 (W48)
Phase II Randomized Trial Comparing Efficacy and Safety of the Maintenance of a HAART Association Protease Inhibitor Containing Versus a Once Daily Antiretroviral Triple Association, in HIV Adult Patients With Undetectable Viral Load.ANRS 099 ALIZE
Primary endpoint: Virological success from W0 to W48
Pilot Study on Efficacy and Safety of a Once Daily FTC, ddI, Efavirenz Combination in Antiretroviral Naive HIV Infected Adults. ANRS 091 MONTANA
Primary endpoint: Virological success